“FCGBP inhibits the development of LSCC and cisplatin resistance through the PIGR/JAK2/STAT3 pathway” (2026) Radiology and Oncology, 60(1), pp. 67–75. Available at: https://radioloncol.com/index.php/ro/article/view/4672 (Accessed: 20 September 2026).